Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

residualCRC

Financiado

Cerrado

MECHANISMS BEHIND RESIDUAL DISEASE IN COLORECTAL CANCER and MODELLING OF THERAPI...

MECHANISMS BEHIND RESIDUAL DISEASE IN COLORECTAL CANCER and MODELLING OF THERAPIES THAT PREVENT RELAPSE Disease relapse is a major complication in colorectal cancer (CRC). At the time of diagnosis, the majority of patients will present with locoregional disease that can be effectively resected by surgery. This intervention is suffic... ver más

31/08/2025

FUNDACIO INSTITUT...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA BIOMEDICA IRB BA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 23M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-07-22

ERC-2019-ADG: ERC Advanced Grant

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACIO INSTITUT DE RECERCA...

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2014-53784-R ANALISIS GENETICO DEL NICHO METASTASICO EN CANCER COLORECTAL 484K€ Cerrado

META-BREAST-CA The role of intracrine receptor ligand interactions in survi... 100K€ Cerrado

PROSTarget PROSTarget Understanding the aggressive nature and key mole... 165K€ Cerrado

PID2019-106247GB-I00 HETEROGENEIDAD GENOMICA DE LAS CELULAS TUMORALES CIRCULANTES 363K€ Cerrado

CHEMOGUIDE Chemotherapy guidance based on efficacy of treatment regimen... 2M€ Cerrado

CAREMORE Cancer Responsiveness Monitoring based on Resistance mutatio... 7M€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2020-07-22
Fecha Fin: 2025-08-31

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA BIOMEDICA IRB BA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 23M€

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Disease relapse is a major complication in colorectal cancer (CRC). At the time of diagnosis, the majority of patients will present with locoregional disease that can be effectively resected by surgery. This intervention is sufficient to cure the primary disease in most cases. Yet, over the course of the following months or years, around 40% of the patients that underwent resection of the primary tumor with curative intention will relapse, generally in the form of metastatic disease. As these metastases eventually interfere with the function of vital organs such as the liver and lungs, patients that undergo relapse have poor prognosis. Recurrent cancer arises from clinically occult tumor cells that have disseminated to foreign organs (disseminated tumor cells or DTCs) before surgical removal of the primary CRC. Although the time window between surgery and relapse offers a good opportunity to prevent metastasis, current therapies are not effective at eliminating DTCs. Thus, there is an important unmet need to develop strategies to target residual disease. Advances in this area will benefit a large proportion of patients. Despite its clinical relevance, the study of residual disease in CRC has been largely neglected and the principles that govern the behavior of DTCs remain unknown. The main reason for this important knowledge gap is that residual tumor cells are difficult to study in patients, as they remain clinically occult. We have recently generated a unique set of compound mutant mice and organoids that reproduce key features of human metastatic CRC. We propose to leverage these new models to study the biology of residual disease. We will characterize the features of DTCs using single cell transcriptional profiling, analyze the influence of driver mutations on DTC behavior, explore mechanisms of immune evasion during the latency phase, and model DTC latency in vivo and in vitro. Our ultimate goal is to design therapies that prevent disease relapse in CRC.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores